1. Home
  2. PLG vs SGHT Comparison

PLG vs SGHT Comparison

Compare PLG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.82

Market Cap

223.4M

Sector

N/A

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$3.45

Market Cap

187.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
SGHT
Founded
2000
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.4M
187.4M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
PLG
SGHT
Price
$1.82
$3.45
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
2.0M
256.8K
Earning Date
04-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$2.30
52 Week High
$4.04
$9.24

Technical Indicators

Market Signals
Indicator
PLG
SGHT
Relative Strength Index (RSI) 44.26 34.65
Support Level $1.82 $3.29
Resistance Level $1.89 $3.76
Average True Range (ATR) 0.11 0.22
MACD 0.04 0.04
Stochastic Oscillator 74.29 7.10

Price Performance

Historical Comparison
PLG
SGHT

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: